Skip to content

Study · Randomized controlled trial · n = 50 · 1994

11 results

Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia.

Eri LM, Tveter KJ

The Journal of urology1 Aug 1994Cited by 22 (Europe PMC)

PMID7516978 (opens in a new tab)DOI10.1016/s0022-5347(17)32760-x (opens in a new tab)PepBankPUB-07516978
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with benign prostatic hyperplasia, leuprolide reduced mean testicular volume by 28.9% compared with placebo (p < 0.001).

    In plain wordsLeuprolide reduced testicular volume compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseTesticular volume
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Measurements

    Testicular volume decrease
    28.9%
    versus placebo

    Source sentences

    Summary
    Mean testicular volume decreased by 28.9% (p < 0.001) compared to placebo.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with benign prostatic hyperplasia, breast changes were not more pronounced with leuprolide than placebo.

    In plain wordsBreast changes were not more pronounced with leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    No significant changeBreast changes
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Breast changes, and loss of energy and vigor were not more pronounced than for patients receiving placebo.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with benign prostatic hyperplasia, loss of energy and vigor was not more pronounced with leuprolide than placebo.

    In plain wordsLoss of energy and vigor was not more pronounced with leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    No significant changeLoss of energy and vigor
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Breast changes, and loss of energy and vigor were not more pronounced than for patients receiving placebo.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with benign prostatic hyperplasia, hemoglobin decreased by 0.8 gm/100 ml during leuprolide treatment (p = 0.0052).

    In plain wordsHemoglobin decreased during leuprolide treatment in patients with benign prostatic hyperplasia.

    Peptide
    Leuprolide
    Outcome
    DecreaseHemoglobin decrease
    Study

    n = 26

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Measurements

    Hemoglobin decrease
    0.8 gm/100 ml
    leuprolide

    Source sentences

    Summary
    Hemoglobin level decreased by 0.8 gm/100 ml. (p = 0.0052) for patients receiving leuprolide.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  5. 05HumanNon-randomized trialSafety outcome

    Among 26 leuprolide-treated patients with benign prostatic hyperplasia, 5 gained more than 3 kg.

    In plain wordsFive of 26 patients receiving leuprolide gained more than 3 kg.

    Peptide
    Leuprolide
    Outcome
    IncreaseWeight gain exceeding threshold
    Study

    n = 26

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Measurements

    Patients with weight gain of more than 3 kg
    5 patients
    leuprolide, of 26 patients

    Source sentences

    Summary
    Of 26 patients receiving leuprolide 5 had a weight gain of more than 3 kg.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  6. 06HumanNon-randomized trialSafety outcome

    Almost all leuprolide-treated patients with benign prostatic hyperplasia experienced hot flushes.

    In plain wordsAlmost all patients receiving leuprolide experienced hot flushes.

    Peptide
    Leuprolide
    Outcome
    Not applicableHot flushes
    Study

    n = 26

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Almost all patients receiving leuprolide experienced hot flushes.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  7. 07HumanNon-randomized trialSafety outcome

    In leuprolide-treated patients with benign prostatic hyperplasia, erectile function was lost during treatment.

    In plain wordsPatients lost erectile function during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseErectile function
    Study

    n = 26

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Erectile function and sexual activity were lost during treatment.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  8. 08HumanNon-randomized trialSafety outcome

    In leuprolide-treated patients with benign prostatic hyperplasia, sexual activity was lost during treatment.

    In plain wordsPatients lost sexual activity during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseSexual activity
    Study

    n = 26

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Erectile function and sexual activity were lost during treatment.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  9. 09HumanNon-randomized trialSafety outcome

    In leuprolide-treated patients with benign prostatic hyperplasia, libido decreased but remained partially retained.

    In plain wordsLibido decreased during leuprolide treatment but remained partially retained.

    Peptide
    Leuprolide
    Outcome
    DecreaseLibido
    Study

    n = 26

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Libido also decreased but was still partially retained.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  10. 10HumanNon-randomized trialOther

    Leuprolide-treated patients with benign prostatic hyperplasia were generally contented with their sexual life during treatment.

    In plain wordsPatients receiving leuprolide were generally contented with their sexual life during treatment.

    Peptide
    Leuprolide
    Outcome
    Not applicableSexual life satisfaction
    Study

    n = 26

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Despite this, patients receiving leuprolide were generally contented with their sexual life during treatment.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.
  11. 11HumanNon-randomized trialSafety outcome

    In patients with benign prostatic hyperplasia, leuprolide side effects bothered some patients but were reversible.

    In plain wordsLeuprolide side effects bothered some patients but were reversible.

    Peptide
    Leuprolide
    Outcome
    Not applicableSide effect burden and reversibility
    Study

    n = 26

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.75 mg every 28 days · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Side effects were bothersome for some patients but were reversible.
    2 context sentences
    Summary · context
    The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia.
    Summary · context
    Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.